Antaros Medical supports SANOFI research in incretin biology

Drug development innovator, Antaros Medical, has entered into a research agreement with leading global healthcare group SANOFI. The project seeks to increase the understanding of the activity of certain incretins and underscores the vital role Antaros Medical plays as a trusted partner to major drug manufacturers.
“The Antaros team has an impressive track record in early clinical experimentation and clinical functional imaging. For this reason we have chosen Antaros as our partner for a series of complex translational medicine studies aiming at improving our insights to incretin biology,” says Dr. Philip Just Larsen, VP Global Head of Diabetes Research and Translational Science at Sanofi.
Under the terms of the agreement, Antaros Medical will apply its innovative MRI and PET imaging techniques to broaden the understanding of incretin biology in diabetes.
Antaros Medical, based in the Bioventure Hub in Mölndal, Sweden, is pioneering new frontiers in innovative MRI and PET imaging techniques and seamless clinical drug development.

For more information about this media release, please contact: Johannes Hulthe at johannes.hulthe@antarosmedical.com

Media release 2016-01-14